Despite the capability of antiretroviral drugs to suppress HIV to undetectable levels, some people living with the human ...
The two-drug regimen dolutegravir/lamivudine is as effective as the three-drug regimen dolutegravir plus tenofovir ...
Primary effectiveness was measured by the number of patients with HIV-1 RNA ≥50 copies/mL at Week 48, as well as the number of patients with a change in CD4 cell count, and the proportion of patients ...
As the first COVID-19 vaccines are rolled out around the world, HIV/AIDS experts and advocates have sought to reassure those ...
Gilead Sciences has announced positive topline results from the Phase 3 ARTISTRY-1 trial. The open-label trial evaluated the treatment responses of adults with HIV who ...
In an article published in The Lancet HIV, authors including Distinguished Professor Denis Nash and Professor Constantin ...
6don MSN
Indian Institute of Science Bengaluru decodes how sugar structures help HIV evade immune response
Bengaluru: Researchers at the Indian Institute of Science (IISc) have uncovered how subtle variations in sugar molecules ...
Review of current evidence indicates immune checkpoint inhibitors offer comparable efficacy and safety for NSCLC in people ...
Gilead's Phase 3 ARTISTRY-1 trial shows its single-tablet HIV regimen of bictegravir and lenacapavir matches the efficacy and safety of current therapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback